[an error occurred while processing this directive]

Journal of Chinese Integrative Medicine ›› 2005, Vol. 3 ›› Issue (4): 266-269.doi: 10.3736/jcim20050406

• Original Clinical Research • Previous Articles     Next Articles

Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer

Wei-rong Zhu1,Lan Zheng1,Yuan-biao Guo1,Jian-ming Yuan2,Xiao-heng Shen1   

  1. 1. Department of Traditional Chinese Medicine, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
    2. Department of Surgery, Ruijin Hospital Luwan Branch, Shanghai Second Medical University, Shanghai 200020, China
  • Received:2005-04-13 Online:2005-07-20 Published:2005-07-20
  • Contact: Xiao-heng Shen E-mail:meilixl@51277.com

RichHTML

1

PDF (PC)

86

Like

Objective

To study the effects of intraperitoneal chemotherapy (IPC) plus Shenmai Injection (SMI) in treating advanced colorectal cancer following radical resections.

Methods

Fifty-eight cases of colorectal cancer in stage B2 and C following radical resections were divided into two groups: SMI+IPC group (36 cases) and IPC group (22 cases). In the SMI+IPC group, IPC (5-fluorouracil combined with cisplatin) plus SMI was administered, while in the IPC group, only IPC was administered. Clinical symptoms, quality of life (Karnofsky score), white blood cell counts, natural killer cells and CD4/CD8 were observed, and disease-free survival (DFS) rate was also evaluated.

Results

The total short-term response rate was 83.33% in the SMI+IPC group, significantly higher than 63.64% in the IPC group (P<0.05). The data of clinical symptoms, quality of life, white blood cell counts, natural killer cells and CD4/CD8 in the SMI+IPC group were also significantly improved as compared with those in the IPC group (P<0.05 or P<0.01). In the SMI+IPC group, 1-, 3- and 5-year DFS rates were 91.7% (33/36), 77.8% (28/36) and 72.2% (26/36) respectively, and those in the IPC group were 90.9% (20/22), 72.7% (16/22) and 45.5% (10/22) respectively. The 5-year DFS rate was significantly improved in the SMI+IPC group as compared with that in the IPC group (P<0.05), while the 1-year and 3-year DFS rates had no significant difference between these two groups.

Conclusion

IPC plus SMI is effective in treating post-operative patients with advanced colorectal cancer.

Key words: Shenmai Injection, Intraperitoneal chemotherapy, Colorectal cancer, Clinical research

CLC Number: 

  • R273

Tab 1

Comparison of clinical symptomatic integrals in 2 groups ($\bar{x}$±s)"

Group n Clinical symptomatic integral
Before treatment After treatment Difference value
SMI+IPC group 36 15.7±3.16 11.4±1.91** 4.3±2.46△△
IPC group 22 15.5±2.51 14.3±2.73* 1.18±2.59

Tab 2

Comparison of life quality in 2 groups ($\bar{x}$±s)"

Group n Clinical symptomatic integral
Before treatment After treatment Difference value
SMI+IPC group 36 69.7±12.72 80.9±13.16** 11.2±9.26△△
IPC group 22 70.6±13.25 70.8±13.82 0.20±6.19

Tab 3

Comparison of white blood cell counts in 2 groups ($\bar{x}$±s, ×109/L)"

Group n White blood cell count
1st month 2nd month 3rd month 4th month 5th month 6th month
SMI+IPC group
Before treatment 36 5.48±2.27 5.43±2.04 5.37±2.32 5.28±1.71 5.21±1.66* 4.82±1.39*
After treatment 36 5.12±1.56 5.06±1.78 5.08±1.83 5.03±1.58** 4.97±1.34** 4.65±1.23**
IPC group
Before treatment 22 5.62±2.20 5.17±1.76 5.04±1.65 4.73±1.48 4.24±1.37 4.05±1.14
After treatment 22 4.77±1.52 4.63±1.55 4.41±1.59 3.82±1.11 3.69±1.25 3.55±1.20

Tab 4

Comparison of NK cells in 2 groups ($\bar{x}$±s, %)"

Group n NKcell
Before treatment After treatment Difference value
SMI+IPC group 36 14.76±2.87 16.98±3.14** 2.22±2.35△△
IPC group 22 14.81±3.14 15.16±3.43 0.35±0.95

Tab 5

Comparison of CD4/CD8 in 2 groups ($\bar{x}$±s)"

Group n CD4/CD8
Before treatment After treatment Difference value
SMI+IPC group 36 1.52±0.16 1.57±0.17** 0.05±0.09△△
IPC group 22 1.50±0.17 1.48±0.18 0.02±0.11

Tab 6

Comparison of DFS rates in 2 groups ($\bar{x}$±s, %)"

Group n Disease-Free Survival rate
1-year 3-year 5-year
SMI+IPC group 36 91.7 (33/36) 77.8 (28/36) 72.2 (26/36)*
IPC group 22 90.9 (20/22) 72.7 (16/22) 45.5 (10/22)
[1] Vaillant JC, Nordlinger B, Deuffic S , et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase Ⅲ trial[J]. Ann Surg, 2000,231(4):457-459
doi: 10.1097/00000658-200004000-00002 pmid: 10749604
[2] O'Connell MJ , Gunderson LL.Adjuvant therapy for adenocarcinoma of the rectum[J]. World J Surg, 1992,16(3):510-515
doi: 10.1007/BF02104456 pmid: 1589989
[3] 王天翔, 袁建明, 金志明 , 等. 胃肠道恶性肿瘤腹腔化疗临床研究[J]. 中华现代外科学杂志, 2004,1(2):129-131
[4] E1ias D, Blot F, El Otmany A , et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy[J]. Cancer, 2001,92(1):71-76
doi: 10.1002/1097-0142(20010701)92:1&lt;&gt;1.0.CO;2-Z
[5] 冯国光, 郁宝铭, 周锡庚 . 腹腔化疗在防治胃肠道癌术后复发的应用[J]. 中国实用外科杂志, 1995,15(12):720-721
[6] 迁谷俊一, 崔向东, 宋方田 . 低渗性顺铂溶液腹腔灌注治疗胃癌腹膜种植[J]. 日本医学介绍, 1998,19(10):440-443
[7] 魏育林, 李亚俊, 刘轩 , 等. 参麦针剂对内毒素所致小鼠全身炎症反应综合征和多器官功能失常综合征保护作用的实验研究[J]. 中国中西医结合杂志, 2001,21(1):47-50
[8] 卫丽, 杨光华, 梁翠微 , 等. 参麦针剂对恶性肿瘤放化疗的骨髓保护作用[J]. 华西药学杂志, 2000,15(6):473-474
doi: 10.3969/j.issn.1006-0103.2000.06.033
[1] Lu-ming Chen, Hui Yu, Da-rong Wu , Xun Hu , Lan Zheng. Investigation on response of the patient-reported outcome scale of the main-symptoms of chronic obstructive pulmonary disease complicated with pulmonary heart disease. Journal of Chinese Integrative Medicine, 2012, 10(9): 970-974.
[2] Ming-xing Zhao, Zhen-hua Dong, Zhong-hai Yu, Shi-yuan Xiao, Ya-ming Li . Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(6): 628-634.
[3] Jie-ning Wang, Sheng Ye, Dong-hai Yu, Hui Zhao, Le-yi Du. Practice and exploration on clinical evaluations of hospital-made Chinese herbal formulas in the Pudong New Area of Shanghai. Journal of Chinese Integrative Medicine, 2012, 10(10): 1084-1087.
[4] Wan-li Gu , Zai-xiang Shi, Yun-xu Yu, Yu-wei Wu, Bao-wei Lu, Ka-kit Hui . Distribution characteristics of syndrome types in essential hypertension. Journal of Chinese Integrative Medicine, 2010, 8(9): 842-847.
[5] Feng-gang Hou , Yi Cen, Jian Guan, Ling-yun Zhu, Xiao-ling Yin. Quantified diagnositic standard for large intestinal cancer of spleen qi deficiency syndrome. Journal of Chinese Integrative Medicine, 2009, 7(9): 814-818.
[6] Deng-hao Liu, Zheng Wang, Zhang-yan Qin. Clinical effects of Shugan Jianpi Recipe on postadolescent acne in women. Journal of Chinese Integrative Medicine, 2009, 7(7): 671-673.
[7] Ya-jie Wang , Ha-fa Que. Clinical study of syndrome differentiation standards for chronic skin ulcer of lower limbs. Journal of Chinese Integrative Medicine, 2009, 7(12): 1139-1144.
[8] Chung-wah Cheng, Zhao-xiang Bian, You-ping Li, David Moher, Tai-xiang Wu, Simon Dagenais, Jing Li, Ting-qian Li. Transparently reporting adverse effects of traditional Chinese medicine interventions in randomized controlled trials. Journal of Chinese Integrative Medicine, 2008, 6(9): 881-886.
[9] Zhao-xiang Bian, David Moher, You-ping Li, Tai-xiang Wu, Simon Dangenais, Chung-wah Cheng, Jing Li, Ting-qian Li. Appropriately selecting and concisely reporting the outcome measures of randomized controlled trials of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(8): 771-775.
[10] Wei-rong Zhu, Shou-jie Zhang, De-hou Zheng, Xiao-heng Shen. Dishen Qufeng Decoction for treating allergic rhinitis: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(7): 700-703.
[11] Fu-lun Li, Bin Li, Rong Xu, Xun Song, Yang Yu, Zheng-cheng Xu. Qinzhu Liangxue Decoction in treatment of blood-heat type psoriasis vulgaris: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(6): 586-589.
[12] Yi-fei Wang, Bo-hua Li, Ming Zhang, Wen-bin Xu, Rong Zhou, Min Zhou. Stage-based treatment of gouty arthritis by combination therapy of traditional Chinese and Western medicines: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(6): 576-580.
[13] Fan-rong Liang, Yong Tang. Acupuncture in treatment of cerebrosis: advances in clinical research over 20 years. Journal of Chinese Integrative Medicine, 2008, 6(6): 561-564.
[14] Yi-ping Chen. Clinical study of integrative medicine in treatment of nephropathy: strategy and innovation. Journal of Chinese Integrative Medicine, 2008, 6(5): 446-448.
[15] Chen Yue, Liang Zhu, Yi-ming Qian. Diagnostic value of assay of brain natriuretic peptide in patients with sepsis of blood-stasis syndrome. Journal of Chinese Integrative Medicine, 2008, 6(3): 266-269.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[8] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[9] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[10] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022
[an error occurred while processing this directive]